Logo image of CDNA

CAREDX INC (CDNA) Stock Price, Quote, News and Overview

NASDAQ:CDNA - Nasdaq - US14167L1035 - Common Stock - Currency: USD

15.17  +0.17 (+1.13%)

After market: 15.17 0 (0%)

CDNA Quote, Performance and Key Statistics

CAREDX INC

NASDAQ:CDNA (5/5/2025, 5:20:02 PM)

After market: 15.17 0 (0%)

15.17

+0.17 (+1.13%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High34.84
52 Week Low12.9
Market Cap843.45M
Shares55.60M
Float53.41M
Yearly DividendN/A
Dividend YieldN/A
PE22.98
Fwd PE14.23
Earnings (Next)07-29 2025-07-29/amc
IPO07-17 2014-07-17


CDNA short term performance overview.The bars show the price performance of CDNA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

CDNA long term performance overview.The bars show the price performance of CDNA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 60 80

The current stock price of CDNA is 15.17 USD. In the past month the price decreased by -12.21%. In the past year, price increased by 2.29%.

CAREDX INC / CDNA Daily stock chart

CDNA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.09 346.84B
AMGN AMGEN INC 13.49 150.57B
VRTX VERTEX PHARMACEUTICALS INC 1724.79 128.59B
GILD GILEAD SCIENCES INC 13.28 128.00B
REGN REGENERON PHARMACEUTICALS 13.62 65.17B
ARGX ARGENX SE - ADR 345.61 40.09B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.58B
ONC BEIGENE LTD-ADR N/A 27.40B
BNTX BIONTECH SE-ADR N/A 24.30B
NTRA NATERA INC N/A 21.40B
SMMT SUMMIT THERAPEUTICS INC N/A 20.81B
BIIB BIOGEN INC 7.7 17.85B

About CDNA

Company Profile

CDNA logo image CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.

Company Info

CAREDX INC

8000 Marina Blvd, 4th Floor

Brisbane California CALIFORNIA 94080 US

CEO: Reginald Seeto

Employees: 647

CDNA Company Website

CDNA Investor Relations

Phone: 14152872300

CAREDX INC / CDNA FAQ

What is the stock price of CAREDX INC today?

The current stock price of CDNA is 15.17 USD. The price increased by 1.13% in the last trading session.


What is the ticker symbol for CAREDX INC stock?

The exchange symbol of CAREDX INC is CDNA and it is listed on the Nasdaq exchange.


On which exchange is CDNA stock listed?

CDNA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CAREDX INC stock?

15 analysts have analysed CDNA and the average price target is 31.68 USD. This implies a price increase of 108.86% is expected in the next year compared to the current price of 15.17. Check the CAREDX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CAREDX INC worth?

CAREDX INC (CDNA) has a market capitalization of 843.45M USD. This makes CDNA a Small Cap stock.


How many employees does CAREDX INC have?

CAREDX INC (CDNA) currently has 647 employees.


What are the support and resistance levels for CAREDX INC (CDNA) stock?

CAREDX INC (CDNA) has a support level at 14.99 and a resistance level at 17.61. Check the full technical report for a detailed analysis of CDNA support and resistance levels.


Is CAREDX INC (CDNA) expected to grow?

The Revenue of CAREDX INC (CDNA) is expected to grow by 11.88% in the next year. Check the estimates tab for more information on the CDNA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CAREDX INC (CDNA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CAREDX INC (CDNA) stock pay dividends?

CDNA does not pay a dividend.


When does CAREDX INC (CDNA) report earnings?

CAREDX INC (CDNA) will report earnings on 2025-07-29, after the market close.


What is the Price/Earnings (PE) ratio of CAREDX INC (CDNA)?

The PE ratio for CAREDX INC (CDNA) is 22.98. This is based on the reported non-GAAP earnings per share of 0.66 and the current share price of 15.17 USD. Check the full fundamental report for a full analysis of the valuation metrics for CDNA.


What is the Short Interest ratio of CAREDX INC (CDNA) stock?

The outstanding short interest for CAREDX INC (CDNA) is 11.37% of its float. Check the ownership tab for more information on the CDNA short interest.


CDNA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CDNA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to CDNA. CDNA has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CDNA Financial Highlights

Over the last trailing twelve months CDNA reported a non-GAAP Earnings per Share(EPS) of 0.66. The EPS increased by 217.86% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.74%
ROA 10.7%
ROE 13.89%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%400%
Sales Q2Q%17.55%
EPS 1Y (TTM)217.86%
Revenue 1Y (TTM)19.07%

CDNA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to CDNA. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of 14.37% and a revenue growth 11.88% for CDNA


Ownership
Inst Owners99.98%
Ins Owners2.87%
Short Float %11.37%
Short Ratio8.11
Analysts
Analysts80
Price Target31.68 (108.83%)
EPS Next Y14.37%
Revenue Next Year11.88%